Xu Z, Meng L, Xie Y, Guo W. lncRNA PCGEM1 strengthens anti-inflammatory and lung protective effects of montelukast sodium in children with cough-variant asthma.
ACTA ACUST UNITED AC 2020;
53:e9271. [PMID:
32520202 PMCID:
PMC7296716 DOI:
10.1590/1414-431x20209271]
[Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2019] [Accepted: 03/13/2020] [Indexed: 12/18/2022]
Abstract
Montelukast sodium is an effective and well-tolerated anti-asthmatic drug. Long
non-coding RNAs (lncRNAs) are involved in the treatment of asthma. Therefore,
this study aimed to investigate the effect of montelukast sodium on children
with cough-variant asthma (CVA) and the role of lncRNA prostate cancer gene
expression marker 1 (PCGEM1) in drug efficacy. The efficacy of montelukast
sodium was evaluated by assessing the release of inflammatory factors and
pulmonary function in CVA children after a 3-month treatment. An ovalbumin
(OVA)-sensitized mouse model was developed to simulate asthmatic conditions.
PCGEM1 expression in clinical peripheral blood samples and lung tissues of
asthmatic mice was determined. Asthmatic mice experienced nasal inhalation of
PCGEM1 overexpression with simultaneous montelukast sodium to investigate the
roles of PCGEM1 in asthma treatment. The NF-κB axis after PCGEM1 overexpression
was detected to explore the underling mechanisms. Consequently, montelukast
sodium contributed to reduced levels of pro-inflammatory factors and improved
pulmonary function in CVA children. PCGEM1 was poorly expressed in
OVA-sensitized asthmatic mice and highly expressed in CVA children with response
to the treatment. PCGEM1 overexpression enhanced the anti-inflammatory effects
and promoted effects on pulmonary function of montelukast sodium in CVA children
and OVA-sensitized asthmatic mice. Furthermore, PCGEM1 inhibited the activation
of the NF-κB axis. This study demonstrated the anti-inflammatory and
lung-protective effects of montelukast sodium on CVA, which was strengthened by
overexpression of PCGEM1. Findings in this study highlighted a potential
anti-asthmatic target of montelukast sodium.
Collapse